FORT WORTH, Texas, March 10 /PRNewswire-FirstCall/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM), announced today that it has entered into a vendor agreement with Independent Medical Co-Op, Inc. (IMCO), the nation's premier association for medical product manufacturers and independent distributors.
IMCO vendors are carefully selected on quality, price, service, integrity and market acceptance, as well as their exceptional support for IMCO members and their customers. Only one of 20 vendors qualify to become an IMCO vendor. Wound Care Innovation's patented advanced wound care collagen product, CellerateRx(R), was selected as a unique product that has unprecedented capabilities and benefits through all phases of wound healing and is FDA cleared for use on all wound types, except for 3rd degree burns.
"As an IMCO vendor, Wound Care Innovations joins an elite growing network of independent distributors with over 1,000 sales people to market CellerateRx throughout the U.S.," said Cathy Bradshaw, president of Wound Care Innovations. "IMCO has grown into a major distribution force in the physician and nursing home markets, while expanding acute care and other market segments. We are excited with the new sales and marketing opportunities this new relationship brings to Wound Care Innovations."
Established in 1981, IMCO is a U.S. leader in medical supply distribution. The Company has established a trusted network of the best independent distributors in the healthcare industry. With over 125 member locations throughout North America, Puerto Rico and the US Virgin Islands, IMCO provides coverage in the Physician, Hospital, Blood Banks, Nursing Home, Lab, Industrial, Dental, Home Care, Government, EMS, and Veterinary markets.
For more information, visit www.imcoinc.com.
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. (OTCBB:WNDM), with its corporate headquarters in Fort Worth, Texas, markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information on the Company, please visit www.Celleraterx.com.
"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
Contact: Product Information Shareholder Relations Cathy Bradshaw Lucy Singleton President Secretary 954-315-9242 817-820-7080
|SOURCE Wound Management Technologies, Inc.|
Copyright©2009 PR Newswire.
All rights reserved